Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life

Surbhi Sidana, MD, Gita Thanarajasingam, MD, Joan Griffin, PhD, Carrie A. Thompson, MD, Michelle Burtis, Rahma Warsame, MD, Jonas Paludo, MD, Andrea Cheville, Morie A Gertz, MD, Angela Dispenzieri, MD, Jose Villasboas, MD, Stephen M Ansell, MD PhD, S. Vincent Rajkumar, MD, Kathleen J Yost, PhD, N. Nora Bennani, MD, Mustaqeem Siddiqui, MD, Yi Lin, MD PhD, Shaji K. Kumar, MD, Amylou C. Dueck, PhD

Blood (2019) 134 (Supplement_1): 794.

https://doi.org/10.1182/blood-2019-121715

Published: 2019

Journal Articles

The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3 -Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

David Cella, PhD, Ellen K. Ritchie, MD, Francesco Fabbiano, Arnaud Pigneux, Yoshinobu Kanda, MD PhD, Cristina Ivanescu, PhD, Bhavik J. Pandya, PharmD, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 3850.

https://doi.org/10.1182/blood-2019-123790

Published: 2019

Journal Articles

Ibrutinib for Chronic Pulmonary Graft-Versus-Host-Disease after Progression on Prior Therapy

Surbhi Singhal, MD, Theresa Brondstetter, RN, David B. Miklos, MD PhD, Debra Kate Tierney, RN, PhD, Joe Hsu, MD, Laveena Chhatwani, MD

Blood (2019) 134 (Supplement_1): 4532.

https://doi.org/10.1182/blood-2019-129171

Published: 2019

Journal Articles

Vasculo-Behcet's Disease: Profile and Management - Single Center Experience

Mohammed Abdullah Alsheef, MD, Kamal Gazal, MD, Nahar Alenizi, MD, Khalid Qushmaq, MD, Mukhtar Alomar, PharmD, Ghaydaa Juma Kullab, MD, Abdul Rehman Z. Zaidi, MBBS

Blood (2019) 134 (Supplement_1): 4955.

https://doi.org/10.1182/blood-2019-130548

Published: 2019

Journal Articles

The Relationship between Hospitalization and Patient-Reported Outcomes (PROs) in Patients with FLT3 -Mutated ( FLT3 mut+ ) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

Ellen K. Ritchie, MD, David Cella, PhD, Francesco Fabbiano, Arnaud Pigneux, Yoshinobu Kanda, MD PhD, Cristina Ivanescu, PhD, Bhavik J. Pandya, PharmD, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 1332.

https://doi.org/10.1182/blood-2019-123779

Published: 2019

Journal Articles

Say hello to TUGSE!

Kyle T. Wright, Olga Pozdnyakova

Blood (2019) 134 (16): 1360.

https://doi.org/10.1182/blood.2019002505

Published: 2019

Journal Articles

Spare the Spleen in ALPS: It Is Not an Expendable Vestigial Organ

V. Koneti Rao, MD FRCPA, Elaine Kulm, Susan Price, Sharon Webster, BSN, Les Folio, MD, Gulbu Uzel, MD, David T Teachey, MD

Blood (2018) 132 (Supplement 1): 2435.

https://doi.org/10.1182/blood-2018-99-117394

Published: 2018

Journal Articles

Understanding the Collateral Damage of Treating Acute Myeloid Leukemia: An Estimate of Patient-Reported Side Effect Rates from a National Survey

Norah Crossnohere, MPH, Daniel R. Richardson, MD MA, B. Douglas Smith, MD, Crystal Reinhart, Bernadette O'Donoghue, Susan Love, MD MBA, John F.P. Bridges, PhD

Blood (2018) 132 (Supplement 1): 3573.

https://doi.org/10.1182/blood-2018-99-116931

Published: 2018

Journal Articles

Decitabine Combined with FB3 As Conditional Regimen for Elderly Acute Myeloid Leukemia Patient with Allogeneic Hematopoietic Stem Cell Transplantation

Shichun Gao, Jia Liu, Kong Peiyan, Li Gao, Cheng Zhang, MD PhD, Yao Liu, Hongju Yan, Lidan Zhu, Defu Zeng, MD, Lei Gao, Xi Zhang

Blood (2018) 132 (Supplement 1): 2108.

https://doi.org/10.1182/blood-2018-99-115926

Published: 2018

Journal Articles

Phase 2 Trial of Single Agent Gedatolisib (PF-05212384), a Dual PI3K/mTOR Inhibitor, for Adverse Prognosis and Relapse/Refractory AML: Clinical and Transcriptomic Results

Jacques Vargaftig, MD PhD, Hassan Farhat, MD, Lionel Ades, MD PhD, Adrien Briaux, Camille Benoist, Isabelle Turbiez, Norbert Vey, MD PhD, Sylvie Glaisner, MD, Céline Callens, PharmD, PhD

Blood (2018) 132 (Supplement 1): 5233.

https://doi.org/10.1182/blood-2018-99-117485

Published: 2018

Journal Articles

Symptom Burden of Busulfan and Melphalan Versus Melphalan Alone for Multiple Myeloma

Loretta A. Williams, PhD MSN, BSN, BA, Muzaffar H. Qazilbash, MD, Qiuling Shi, MD PhD, Qaiser Bashir, MD MBBS, Huei K. Lin, MS, Charles S. Cleeland, PhD, Richard E. Champlin, MD

Blood (2017) 130 (Supplement 1): 681.

https://doi.org/10.1182/blood.V130.Suppl_1.681.681

Published: 2017

Journal Articles

Sirolimus Is Effective in Refractory Immune Thrombocytopenia: Results of an Open-Label Prospective Multicenter Trial in China

Blood (2017) 130 (Supplement 1): 4728.

https://doi.org/10.1182/blood.V130.Suppl_1.4728.4728

Published: 2017

Journal Articles

Omacetaxine Mepesuccinate for Patients with Higher-Risk MDS and CMML after Failure of Hypomethylating Agents: A Phase II Trial

Nicholas J Short, MD, Guillermo Garcia-Manero, MD, Kiran Naqvi, MDMPH, Steven Kornblau, MD, Koichi Takahashi, MD, Guillermo Montalban-Bravo, MD, Rita Khouri, Michael Andreeff, MD PhD, Marina Konopleva, MD PhD, Courtney D. DiNardo, MDMSc, Yesid Alvarado, MD, Marie Ghosn, Zeev Estrov, MD, Prithviraj Bose, MD, Rubiul Islam, Xiao Dong, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD

Blood (2017) 130 (Supplement 1): 2967.

https://doi.org/10.1182/blood.V130.Suppl_1.2967.2967

Published: 2017

Journal Articles

A Phase II Trial of Omacetaxine Mepesuccinate for Patients with High-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agents

Nicholas J. Short, MD, Guillermo Garcia-Manero, MD, Kiran Naqvi, MD, Steven M. Kornblau, MD, Abhishek Maiti, MBBS, Marina Konopleva, MD PhD, Courtney D DiNardo, MD, Koichi Takahashi, MD, Yesid Alvarado, MD, Maro Ohanian, DO, Zeev Estrov, MD, Prithviraj Bose, MD, Michael Andreeff, MD PhD, Rabiul Islam, Xiao Dong, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD

Blood (2016) 128 (22): 4328.

https://doi.org/10.1182/blood.V128.22.4328.4328

Published: 2016

Journal Articles

Management of Relapsed Acute Promyelocytic Leukemia Post ATO Upfront Therapy: Open-Labeled Phase II Study Evaluating Role of Proteasome Inhibition

Vikram Mathews, MD DM, Anu Korula, MD DM, Uday Kulkarni, MD, Saravanan Ganesan, MSc, Sachin David, MSc, Ansu Abu Alex, MSc, Nisham PN, MD DM, Aby Abraham, MD DM, Alok Srivastava, Kavitha M Lakshmi, MSc, Poonkuzhali Balasubramanian, MSc PhD, Biju George, MD DM

Blood (2016) 128 (22): 446.

https://doi.org/10.1182/blood.V128.22.446.446

Published: 2016

Journal Articles

RCHOP-21 Vs. RCHOP-14 for the Treatment of Newly Diagnosed Diffuse Large B Cell Lymphoma: A Prospective Randomized Phase III Clinical Trial from Cswog

Tongyu Lin, He Huang, Xueying Li, Chengcheng Guo, Huangming Hong, Xiaohong Fu, Xiaoting Lin, Xiaojie Fang, Zhao Wang, Zhongjun Xia, MD

Blood (2015) 126 (23): 2690.

https://doi.org/10.1182/blood.V126.23.2690.2690

Published: 2015

Journal Articles

Brincidofovir (BCV) Prophylaxis for Herpes Simplex Virus (HSV) and Varicella Zoster Virus (VZV) after Hematopoietic Cell Transplantation (HCT): Clinical Experience at Memorial Sloan-Kettering Cancer Center

Yeon Joo Lee, MD MPH, Seong Jin Kim, MPH, Daniel Burack, BS, Yao-Ting Hayden Huang, PhD MPH, Esperanza B Papadopoulos, MD, Ann A. Jakubowski, MD PhD, Genovefa A Papanicolaou, MD

Blood (2015) 126 (23): 2123.

https://doi.org/10.1182/blood.V126.23.2123.2123

Published: 2015

Journal Articles

Complete Resolution of Extensive Chronic Graft-Versus-Host Disease with Ibrutinib

Audrey Scholoff, MSN, Gloria Obi, PhD, Kelty R. Baker, MD, George Carrum, MD, Rammurti T Kamble, MD

Blood (2015) 126 (23): 5474.

https://doi.org/10.1182/blood.V126.23.5474.5474

Published: 2015

Journal Articles

Development of Somatic NRAS Mutation Associated with Rapid Transition from Germline GATA2 Mutation Associated Myelodysplastic Syndrome to Acute Myeloid Leukemia

Yanqin Yang, MDMSc, Yubo Zhang, PhD, Jun Zhu, PhD, Catherine E. Lai, MD, Jingrong Tang, MD PhD, Lisa J. McReynolds, MD PhD, Amy P Hsu, Dennis D. Hickstein, MD, Danielle M. Townsley, MD, Steven M. Holland, MD, Katherine R. Calvo, MD, PhD, Christopher S. Hourigan, MDPhD

Blood (2015) 126 (23): 3616.

https://doi.org/10.1182/blood.V126.23.3616.3616

Published: 2015

Journal Articles

Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD)

H. Jean Khoury, Vamsi Kota, M.B;B.S, Martha Arellano, MD, Stephanie L Bauer, ANP, Anand P Jillella, MD, Amelia Langston, MD, Zaid Al-Kadhimi, MD, Zachariah DeFilipp, MD, Audrey S Kim, RN, Elliott F. Winton, MD, John F Dipersio, MD PhD

Blood (2015) 126 (23): 1938.

https://doi.org/10.1182/blood.V126.23.1938.1938

Published: 2015

NARROW

Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life

The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3 -Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

Ibrutinib for Chronic Pulmonary Graft-Versus-Host-Disease after Progression on Prior Therapy

Vasculo-Behcet's Disease: Profile and Management - Single Center Experience

The Relationship between Hospitalization and Patient-Reported Outcomes (PROs) in Patients with FLT3 -Mutated ( FLT3 mut+ ) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

Say hello to TUGSE!

Spare the Spleen in ALPS: It Is Not an Expendable Vestigial Organ

Understanding the Collateral Damage of Treating Acute Myeloid Leukemia: An Estimate of Patient-Reported Side Effect Rates from a National Survey

Decitabine Combined with FB3 As Conditional Regimen for Elderly Acute Myeloid Leukemia Patient with Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2 Trial of Single Agent Gedatolisib (PF-05212384), a Dual PI3K/mTOR Inhibitor, for Adverse Prognosis and Relapse/Refractory AML: Clinical and Transcriptomic Results

Symptom Burden of Busulfan and Melphalan Versus Melphalan Alone for Multiple Myeloma

Sirolimus Is Effective in Refractory Immune Thrombocytopenia: Results of an Open-Label Prospective Multicenter Trial in China

Omacetaxine Mepesuccinate for Patients with Higher-Risk MDS and CMML after Failure of Hypomethylating Agents: A Phase II Trial

A Phase II Trial of Omacetaxine Mepesuccinate for Patients with High-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agents

Management of Relapsed Acute Promyelocytic Leukemia Post ATO Upfront Therapy: Open-Labeled Phase II Study Evaluating Role of Proteasome Inhibition

RCHOP-21 Vs. RCHOP-14 for the Treatment of Newly Diagnosed Diffuse Large B Cell Lymphoma: A Prospective Randomized Phase III Clinical Trial from Cswog

Brincidofovir (BCV) Prophylaxis for Herpes Simplex Virus (HSV) and Varicella Zoster Virus (VZV) after Hematopoietic Cell Transplantation (HCT): Clinical Experience at Memorial Sloan-Kettering Cancer Center

Complete Resolution of Extensive Chronic Graft-Versus-Host Disease with Ibrutinib

Development of Somatic NRAS Mutation Associated with Rapid Transition from Germline GATA2 Mutation Associated Myelodysplastic Syndrome to Acute Myeloid Leukemia

Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only